vs
Atlanta Braves Holdings, Inc.（BATRA）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Atlanta Braves Holdings, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.7倍（$61.3M vs $35.5M），Atlanta Braves Holdings, Inc.净利率更高（-67.6% vs -304.2%，领先236.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 17.6%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -52.5%）
亚特兰大勇士控股有限公司是一家体育娱乐类控股企业，核心持有并运营美国职业棒球大联盟旗下的亚特兰大勇士队，同时开展场馆周边商住开发、活动承办、周边商品销售及传媒业务，服务美国东南部及全球棒球迷。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
BATRA vs RXRX — 直观对比
营收规模更大
BATRA
是对方的1.7倍
$35.5M
营收增速更快
RXRX
高出664.1%
17.6%
净利率更高
BATRA
高出236.6%
-304.2%
两年增速更快
RXRX
近两年复合增速
-52.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $61.3M | $35.5M |
| 净利润 | $-41.4M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | -81.2% | -304.8% |
| 净利率 | -67.6% | -304.2% |
| 营收同比 | 17.6% | 681.7% |
| 净利润同比 | -116.7% | 39.6% |
| 每股收益（稀释后） | $-0.64 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BATRARXRX
| Q4 25 | $61.3M | $35.5M | ||
| Q3 25 | $311.5M | $5.2M | ||
| Q2 25 | $312.4M | $19.2M | ||
| Q1 25 | $47.2M | $14.7M | ||
| Q4 24 | $52.1M | $4.5M | ||
| Q3 24 | $290.7M | $26.1M | ||
| Q2 24 | $282.9M | $14.4M | ||
| Q1 24 | — | $13.8M |
净利润BATRARXRX
| Q4 25 | $-41.4M | $-108.1M | ||
| Q3 25 | $30.0M | $-162.3M | ||
| Q2 25 | $29.5M | $-171.9M | ||
| Q1 25 | $-41.4M | $-202.5M | ||
| Q4 24 | $-19.1M | $-178.9M | ||
| Q3 24 | $10.0M | $-95.8M | ||
| Q2 24 | $29.1M | $-97.5M | ||
| Q1 24 | — | $-91.4M |
毛利率BATRARXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率BATRARXRX
| Q4 25 | -81.2% | -304.8% | ||
| Q3 25 | 12.5% | -3327.6% | ||
| Q2 25 | 13.4% | -916.8% | ||
| Q1 25 | -94.2% | -1297.9% | ||
| Q4 24 | -35.8% | -4042.4% | ||
| Q3 24 | 2.2% | -377.1% | ||
| Q2 24 | 8.8% | -697.4% | ||
| Q1 24 | — | -698.4% |
净利率BATRARXRX
| Q4 25 | -67.6% | -304.2% | ||
| Q3 25 | 9.6% | -3135.3% | ||
| Q2 25 | 9.4% | -894.2% | ||
| Q1 25 | -87.7% | -1373.3% | ||
| Q4 24 | -36.7% | -3935.5% | ||
| Q3 24 | 3.4% | -367.5% | ||
| Q2 24 | 10.3% | -676.6% | ||
| Q1 24 | — | -662.4% |
每股收益（稀释后）BATRARXRX
| Q4 25 | $-0.64 | $-0.17 | ||
| Q3 25 | $0.47 | $-0.36 | ||
| Q2 25 | $0.46 | $-0.41 | ||
| Q1 25 | $-0.66 | $-0.50 | ||
| Q4 24 | $-0.29 | $-0.56 | ||
| Q3 24 | $0.16 | $-0.34 | ||
| Q2 24 | $0.46 | $-0.40 | ||
| Q1 24 | — | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $99.9M | $743.3M |
| 总债务越低越好 | $738.6M | $9.6M |
| 股东权益账面价值 | $526.0M | $1.1B |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 1.40× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资BATRARXRX
| Q4 25 | $99.9M | $743.3M | ||
| Q3 25 | $82.2M | $659.8M | ||
| Q2 25 | $96.2M | $525.1M | ||
| Q1 25 | $244.7M | $500.5M | ||
| Q4 24 | $110.1M | $594.4M | ||
| Q3 24 | $100.9M | $427.6M | ||
| Q2 24 | $121.2M | $474.3M | ||
| Q1 24 | — | $296.3M |
总债务BATRARXRX
| Q4 25 | $738.6M | $9.6M | ||
| Q3 25 | $759.9M | $11.9M | ||
| Q2 25 | $703.1M | $14.2M | ||
| Q1 25 | $699.5M | $16.4M | ||
| Q4 24 | $617.1M | $19.0M | ||
| Q3 24 | $640.1M | $20.5M | ||
| Q2 24 | $600.0M | $22.9M | ||
| Q1 24 | — | — |
股东权益BATRARXRX
| Q4 25 | $526.0M | $1.1B | ||
| Q3 25 | $560.3M | $1.0B | ||
| Q2 25 | $522.8M | $919.1M | ||
| Q1 25 | $486.1M | $933.9M | ||
| Q4 24 | $524.2M | $1.0B | ||
| Q3 24 | $530.4M | $524.6M | ||
| Q2 24 | $512.7M | $584.4M | ||
| Q1 24 | — | $401.2M |
总资产BATRARXRX
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.7B | $1.4B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.7B | $1.3B | ||
| Q4 24 | $1.5B | $1.4B | ||
| Q3 24 | $1.6B | $726.5M | ||
| Q2 24 | $1.6B | $775.9M | ||
| Q1 24 | — | $557.8M |
负债/权益比BATRARXRX
| Q4 25 | 1.40× | 0.01× | ||
| Q3 25 | 1.36× | 0.01× | ||
| Q2 25 | 1.34× | 0.02× | ||
| Q1 25 | 1.44× | 0.02× | ||
| Q4 24 | 1.18× | 0.02× | ||
| Q3 24 | 1.21× | 0.04× | ||
| Q2 24 | 1.17× | 0.04× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $26.4M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | 0.0% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流BATRARXRX
| Q4 25 | $26.4M | $-46.1M | ||
| Q3 25 | $-88.8M | $-117.4M | ||
| Q2 25 | $-8.1M | $-76.4M | ||
| Q1 25 | $95.8M | $-132.0M | ||
| Q4 24 | $28.9M | $-115.4M | ||
| Q3 24 | $-69.0M | $-59.2M | ||
| Q2 24 | $-34.3M | $-82.2M | ||
| Q1 24 | — | $-102.3M |
自由现金流BATRARXRX
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | $-82.3M | $-79.6M | ||
| Q1 25 | $76.3M | $-133.8M | ||
| Q4 24 | $16.8M | $-116.7M | ||
| Q3 24 | $-85.5M | $-63.8M | ||
| Q2 24 | $-64.1M | $-83.4M | ||
| Q1 24 | — | $-109.0M |
自由现金流率BATRARXRX
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | -26.3% | -413.9% | ||
| Q1 25 | 161.5% | -907.4% | ||
| Q4 24 | 32.3% | -2567.7% | ||
| Q3 24 | -29.4% | -244.6% | ||
| Q2 24 | -22.7% | -578.5% | ||
| Q1 24 | — | -789.9% |
资本支出强度BATRARXRX
| Q4 25 | 0.0% | 3.5% | ||
| Q3 25 | 0.0% | 4.7% | ||
| Q2 25 | 23.7% | 16.4% | ||
| Q1 25 | 41.3% | 12.4% | ||
| Q4 24 | 23.2% | 28.6% | ||
| Q3 24 | 5.7% | 17.5% | ||
| Q2 24 | 10.5% | 8.2% | ||
| Q1 24 | — | 48.2% |
现金转化率BATRARXRX
| Q4 25 | — | — | ||
| Q3 25 | -2.96× | — | ||
| Q2 25 | -0.28× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.89× | — | ||
| Q2 24 | -1.18× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BATRA
| Baseball | $34.8M | 57% |
| Mixed Use Development Segment | $26.5M | 43% |
RXRX
暂无分部数据
